
|Videos|March 23, 2011
Dr. Kris on the Crizotinib Clinical Trials
Author(s)Mark G. Kris, MD, FASCO
Dr. Mark G. Kris from Memorial Sloan-Kettering Cancer Center on the Crizotinib Clinical Trials
Advertisement
Mark G. Kris, MD, chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, describes the goal in cancer care has been to know enough about cancer to find a characteristic that is a weakness to the cancer and exploit it.
When discussing the clinical trial Kris explains that only patients with an EML4-ALK translocation were allowed into the crizotinib clinical trial. He compares crizotinib to imatinib in BCR-ABL patients.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
Outcomes With Bridging Therapy Correlate With Cilta-Cel Efficacy, Safety in Multiple Myeloma
4
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
5






































